Motelity Tablet 1 mg

Motelity (Prucalopride Succinate 1 mg tablet) by Nuvista Pharma Ltd is a prescription drug for chronic constipation in adults unresponsive to laxatives. Priced at ৳14.00 per unit, it comes in strips of 10 tablets (৳140.00) or packs of 2×10 (৳280.00). This tablet form requires storage below 30°C in its original bottle.

As a selective 5-HT4 receptor agonist, Motelity enhances colonic motility by stimulating acetylcholine release without affecting hERG channels – reducing cardiovascular risks. It specifically targets gastrointestinal smooth muscles, promoting contraction and easing stool movement. Patients report effects within 3-4 hours of dosage.

Dosage guidelines:

• Adults: 2 mg once daily (max dose)
• Elderly: Start with 1 mg, may increase to 2 mg
• Contraindicated for under-18s

Common side effects like headache (22%), abdominal pain (15%), and diarrhea (9%) typically diminish within days. Though drug interactions are rare, caution is advised with strong CYP3A4/P-gp inhibitors like ketoconazole which may increase serum concentration by 40%.

Pregnant/breastfeeding women should avoid Motelity despite no teratogenic evidence in animal studies. For overdose management (symptoms: severe diarrhea), focus on electrolyte rehydration rather than specific antidotes.

Adults: 2 mg once daily before/after meals. Elderly: Start with 1 mg, may increase to 2 mg. Renal impairment (GFR <30): 1 mg daily. Severe hepatic impairment: Start with 1 mg. Treatment duration based on clinical response.

The most frequently reported adverse reactions associated with Motelity therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain), nausea and diarrhoea. The adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. Other adverse reactions have been reported occasionally. The majority of adverse events were mild to moderate in intensity.

Contraindicated in pregnancy. Avoid during lactation. Contraception required. No teratogenicity in animal studies, but human data insufficient.

Dose adjustment needed in renal/hepatic impairment. Caution in lactose intolerance. May reduce oral contraceptive efficacy. Monitor electrolytes regularly.

Pediatric: Contraindicated <18 years. Geriatric: Start with 1 mg. Renal: 1 mg/day if GFR <30. Hepatic: Start 1 mg in Child-Pugh C.

An overdose may result in symptoms resulting from an exaggeration of prucalopride’s known pharmacodynamic effects and include headache, nausea and diarrhoea. Specific treatment is not available for Motelity overdose. Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted, as required. Extensive fluid loss by diarrhoea or vomiting may require correction of electrolyte disturbances.